Literature DB >> 32530714

Cigarette Smoking and COVID-19: A Complex Interaction.

Francesca Polverino1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32530714      PMCID: PMC7397788          DOI: 10.1164/rccm.202005-1646LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
To the Editor: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease (COVID-19), has expanded from Wuhan throughout China and is being exported to a growing number of countries worldwide. Despite the fact that the main complications of COVID-19 affect the lung, the prevalence of current smokers among hospitalized patients with COVID-19 has been reported consistently lower than the prevalence of smokers among the general population for that specific geographical area (1), even if one might have anticipated the opposite. Thus, the epidemiological data seem to question the role of coexisting active smoking as a risk factor for COVID-19 pneumonia. The data from Cai and colleagues, recently published in the Journal (2), report upregulation of pulmonary ACE2 (angiotensin-converting enzyme 2) gene expression in ever-smokers compared with nonsmokers in several transcriptomic data sets of lung samples from healthy never- and ever-smokers and patients with chronic obstructive pulmonary disease. Also, they report an increase in ACE2-producing goblet cells in ever-smoker versus never-smoker lungs. These findings have putatively important implications for patients with COVID-19 because ACE2 has been shown to be the receptor used by SARS-CoV-2 to enter the host cells (3) and yet seem in contrast with the consolidated epidemiological data worldwide indicating a low prevalence of active smokers among patients with COVID-19. Cigarette smoke induces epigenetic modifications of the bronchial epithelium, leading to mucous (goblet) cell metaplasia. As goblet cells are a major source of ACE2 in the lung, this could, in part, justify the increased levels of ACE2 found by Cai and colleagues in lungs of smokers. However, goblet cells are also the main source of mucous, which provides an essential first host barrier to inhaled pathogens that can prevent pathogen invasion and subsequent infection. Additional factors could play a role in the interaction between active smoking and SARS-CoV-2. First, naturally occurring structural changes in the ACE2 allelic variants can interfere with the intermolecular interactions of such variants with SARS‐CoV‐2 spike protein (4). It is conceivable that, upon cigarette smoke (or nicotine?) stimulation, some ACE2 allelic variants that inhibit the SARS-CoV-2 binding may undergo positive selection. Second, nicotine interacts with many components of the RAS (renin–angiotensin system) in multiple organ systems. In the ACE/AT-II (angiotensin II)/AT1R (angiotensin1 receptor) arm, nicotine increases the expression and/or activity of renin, ACE, and AT1R, whereas, in the compensatory ACE2/angiotensin (1–7) arm, nicotine downregulates the expression and/or activity of ACE2 and AT2R (5). How these findings fit with the ones from Cai and colleagues is worth investigation. Interestingly, activation of nicotinic receptors can lead to enhanced protease activation that may cleave and activate the spike protein of SARS-CoV for membrane fusion (5). This effect may counterbalance the increase in ACE2 levels observed in the lungs of smokers by Cai and colleagues. Third, ACE2 knockout mice exposed to cigarette smoke exhibit increased pulmonary inflammation with activation of metalloproteinases (6) that could, in part, contribute to the inactivation or modification of ACE2 in the lungs of the smokers. Last, though it is possible that cigarette smoke increases the ACE2 expression by the bronchial epithelium, thus facilitating the entry of SARS-CoV-2, this does not necessarily translate into a higher risk for developing COVID-19 pneumonia. To conclude, what is unchallengeable is that cigarette smoke is detrimental for the lungs in several ways, and further studies are needed to clarify the reasons behind the reported low prevalence of current smokers among hospitalized patients with COVID-19. The effect of current smoking on SARS-CoV-2 infection is a delicate and complex topic that should be addressed meticulously before delivering messages that could be misinterpreted.
  5 in total

Review 1.  Nicotine and the renin-angiotensin system.

Authors:  Joshua M Oakes; Robert M Fuchs; Jason D Gardner; Eric Lazartigues; Xinping Yue
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-08       Impact factor: 3.619

2.  Alternative Roles of STAT3 and MAPK Signaling Pathways in the MMPs Activation and Progression of Lung Injury Induced by Cigarette Smoke Exposure in ACE2 Knockout Mice.

Authors:  Yi-Han Hung; Wen-Yeh Hsieh; Jih-Sheng Hsieh; Fon-Chang Liu; Chin-Hung Tsai; Li-Che Lu; Chen-Yi Huang; Chien-Liang Wu; Chih-Sheng Lin
Journal:  Int J Biol Sci       Date:  2016-02-12       Impact factor: 6.580

3.  Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2.

Authors:  Guoshuai Cai; Yohan Bossé; Feifei Xiao; Farrah Kheradmand; Christopher I Amos
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

4.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

5.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  5 in total
  20 in total

1.  Outcomes of Patients with COPD Hospitalized for Coronavirus Disease 2019.

Authors:  Daniel A Puebla Neira; Abigail Watts; Justin Seashore; Alexander Duarte; Shawn P Nishi; Efstathia Polychronopoulou; Yong-Fang Kuo; Jacques Baillargeon; Gulshan Sharma
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

2.  Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung.

Authors:  Maya Hassane; Zahraa Rahal; Nareg Karaoghlanian; Jiexin Zhang; Ansam Sinjab; Justin W Wong; Wei Lu; Paul Scheet; J Jack Lee; Maria Gabriela Raso; Luisa M Solis; Junya Fujimoto; Hassan Chami; Alan L Shihadeh; Humam Kadara
Journal:  Cancer Prev Res (Phila)       Date:  2022-07-05

Review 3.  COVID-19 infection and its consequences among surgical oncology patients: A systematic analysis, meta-analysis and meta-regression.

Authors:  Mona Kamal; Massimo Baudo; Shon Shmushkevich; Yimin Geng; Ehab Hanna; Ryan P Goepfert; Carol M Lewis; Mohamed Rahouma
Journal:  J Surg Oncol       Date:  2022-01-11       Impact factor: 2.885

4.  Pre-COVID-19 lung function and other risk factors for severe COVID-19 in first responders.

Authors:  Michael D Weiden; Rachel Zeig-Owens; Ankura Singh; Theresa Schwartz; Yang Liu; Brandon Vaeth; Anna Nolan; Krystal L Cleven; Karen Hurwitz; Shenecia Beecher; David J Prezant
Journal:  ERJ Open Res       Date:  2021-01-25

Review 5.  A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations.

Authors:  Arunkumar Krishnan; James P Hamilton; Saleh A Alqahtani; Tinsay A Woreta
Journal:  Intern Emerg Med       Date:  2021-01-16       Impact factor: 3.397

6.  Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.

Authors:  Sandro Giannini; Giovanni Passeri; Giovanni Tripepi; Stefania Sella; Maria Fusaro; Gaetano Arcidiacono; Marco Onofrio Torres; Alberto Michielin; Tancredi Prandini; Valeria Baffa; Andrea Aghi; Colin Gerard Egan; Martina Brigo; Martina Zaninotto; Mario Plebani; Roberto Vettor; Paola Fioretto; Maurizio Rossini; Alessandro Vignali; Fabrizio Fabris; Francesco Bertoldo
Journal:  Nutrients       Date:  2021-01-14       Impact factor: 5.717

7.  Response to "Potential for bias in assessing risk and protective factors for COVID-19: Commentary on Conlon et al.'s 'Impact of the influenza vaccination on COVID-19 infection rates and Severity'".

Authors:  Anna Conlon; Carmel Ashur; Laraine Washer; Kim A Eagle; Marion A Hofmann Bowman
Journal:  Am J Infect Control       Date:  2021-08       Impact factor: 2.918

Review 8.  Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review).

Authors:  Sergej Nadalin; Hrvoje Jakovac; Vjekoslav Peitl; Dalibor Karlović; Alena Buretić-Tomljanović
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

9.  Lower Gene Expression of Angiotensin Converting Enzyme 2 Receptor in Lung Tissues of Smokers with COVID-19 Pneumonia.

Authors:  Francesca Lunardi; Francesco Fortarezza; Luca Vedovelli; Federica Pezzuto; Annalisa Boscolo; Marco Rossato; Roberto Vettor; Anna Maria Cattelan; Claudia Del Vecchio; Andrea Crisanti; Paolo Navalesi; Dario Gregori; Fiorella Calabrese
Journal:  Biomolecules       Date:  2021-05-26

10.  Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond.

Authors:  Jennifer M Croswell; Douglas A Corley; Jennifer Elston Lafata; Jennifer S Haas; John M Inadomi; Aruna Kamineni; Debra P Ritzwoller; Anil Vachani; Yingye Zheng
Journal:  Prev Med       Date:  2021-06-30       Impact factor: 4.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.